Abstract 15745: Tenascin-c Levels and Clinical Importance in Pulmonary Arterial Hypertension
Background: Prognostic markers are known to have an important value in guiding treatment of pulmonary arterial hypertension (PAH) which is associated with high mortality and morbidity. The prognostic importance of some biomarkers like BNP has been shown and used in the routine course of PAH. Tenacsin-C (TNC) is a glycoprotein located in the extracellular matrix which has an important role in PAH pathophysiology. However, the clinical relevance of PAH and TNC is unknown. In this study, we investigated the plasma levels of TNC in patients with PAH as a possible prognostic marker.
Methods: Study population consisted of 45 PAH (29 women, mean age: 32±9 years, 34 with PAH associated with congenital heart disease, 9 idiopathic PAH and 2 chronic thromboembolic pulmonary hypertension) patients who were followed-up in our PAH centre. Twenty age-sex matched healthy subjects served as the control-group. Plasma TNC levels were measured using ELISA-method. All patients were evaluated with transthoracic echocardiography including assessment of right ventricle, six minute walk test, and NT-proBNP levels simultaneously, which are all known to have prognostic value in PAH. Data were comparatively evaluated using appropriate statistical analysis.
Results: TNC levels in patients with PAH were significantly higher, compared to healthy controls (61.9±20.7 ng/mL versus 12.6±5.6 ng/mL, respectively, p<0.0001). There was no significant relationship between age, gender, and TNC levels. There was a significant positive correlation between TNC levels in PAH group and functional class (rho=0.355, p=0.017) and NT-proBNP (rho=0.5, p=0.001) levels, whereas there was a significant negative correlation between TNC levels and fractional area change (FAC, rho=-0.33, p=0.035) and tricuspid annular plane systolic excursion (TAPSE, rho=-0.495, p=0.006).
Conclusions: TNC levels are substantially increased in PAH. There is a significant association between TNC levels and parameters with proved prognostic value in PAH, such as functional class, TAPSE, FAC, and NT-proBNP levels. All of these data suggest that TNC levels in patients with PAH may be a new prognostic biomarker. Further prospective studies are needed to confirm this statement.
Author Disclosures: O. Vuran: None. M.L. Kayikcioglu: None. S. Nalbantgil: None. O. Musayev: None. H.S. Kemal: None. N. Mogulkoc: None. L.H. Can: None. K.H. Kultursay: None.
- © 2014 by American Heart Association, Inc.